Trials, Trips, and Tribulations: Pathways for Implementing Psychedelic therapy in Ireland

Abstract Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale Phase 3 trials, such as those evaluating psilocybin for treatment-resistant depression (TRD), have shown more modest effects, and further findings from ongoing trials are awaited. Despite the absence of regulatory approvals from the United States (U.S.) Food and Drug Administration (FDA) and European Medicines Agency (EMA), a small but growing number of countries have permitted psychedelic therapies within regulated clinical settings. Across these divergent international approaches, the long-term trajectory and real-world impact of these therapies within public health systems remain uncertain. In anticipation of potential future approval, Ireland has an opportunity to draw on international experience and proactively plan for the integration of psychedelic therapies. Building on emerging evidence, international frameworks, and Ireland-specific policy and health system features, this paper examines the challenges of integrating psychedelic therapies into the Irish public healthcare system. These challenges span regulatory approval, Health Technology Assessment (HTA), service implementation, workforce capacity, and the evaluation of long-term patient outcomes. The aim is to inform policymakers, practitioners, and researchers about key system-level considerations.